IDH2 and central nervous system cancer: This finding corresponds to that of their previous study (Xing et al., 2017) of 42 astrocytomas, in which the rCBVmax (1.41 ± 0.50) of IDH-mutated gliomas was significantly lower than that of IDH-wildtype gliomas (3.47 ± 2.34) (p = 0.004) [50] (Table 2).